Next Phase Newsletter

A venture fund of a global firm that provides software-based services to multiple industries, including healthcare and the life sciences does both venture investing and forms strategic partnerships with companies that are aligned with the firm’s current or future services. As an investor, the firm will generally invest between $200K-3M in seed-series A rounds. For partnerships, the firm is looking for companies looking to scale, potentially working in concert to build clients. The firm will invest and partner globally.

The firm invests in companies developing software-based technologies. Examples of the firm’s services include software for healthcare, such as hospital automation and clinical workflow, as well as virtual care and medical adherence, among others. In the life sciences space, the firm is interested in technologies such as software for connected devices, AI/ML platforms for drug discovery, as well as cell or gene therapies, or decentralized clinical trials, as examples.

The firm is only interested in companies that represent a strategic fit, either for currently offered services, or for complementary services that could expand the firm’s portfolio of services.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Canada was founded by a team with a successful track record of identifying, building, and growing life science companies. The firm recently launched a new fund through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage VC fund formed by alumni of a top tier university currently has $100M under management and focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.

The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based private investment office makes direct investments into early stage healthcare and technology companies. The firm is active across sectors and geographies, favoring recurring revenue, capital efficiency, and durable competitive advantage. Its permanent capital base allows the team to respond to opportunities without mandate constraints or fundraising concerns.

The firm is open to sectors and subsectors in the life science space including healthcare IT, digital health, medical devices and diagnostics.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment. Due to the firm’s capital base they can be more flexible in terms of investment timeframe and have a longer exit horizon than other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm is a single family office of Maryland and New Jersey-based family interests. While the firm is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. FoxHill prefers A round and later stage companies. Pre-A interest depends upon technology stage. Our preferred geography is North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics and other immune-directed therapies. The firm generally will not consider single target small molecules, biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com